CHEK2 Variants and Prostate Cancer
Author Information
Author(s): Seppälä E H, Ikonen T, Mononen N, Autio V, Rökman A, Matikainen M P, Tammela T L J, Schleutker J
Primary Institution: University of Tampere and Tampere University Hospital
Hypothesis
Does the CHEK2 gene play a significant role in hereditary prostate cancer susceptibility in the Finnish population?
Conclusion
The CHEK2 1100delC mutation is associated with a positive family history of prostate cancer, suggesting it contributes to familial prostate cancer risk.
Supporting Evidence
- The CHEK2 1100delC mutation was found in 3.3% of patients with hereditary prostate cancer.
- The I157T variant was found in 10.8% of patients with hereditary prostate cancer.
- The study identified five sequence variants in the CHEK2 gene among patients.
Takeaway
Some people have a gene called CHEK2 that can make them more likely to get prostate cancer, especially if their family members have had it too.
Methodology
The study involved analyzing CHEK2 mutations in families with hereditary prostate cancer and comparing them to a control group of healthy male blood donors.
Potential Biases
Potential bias due to the historical isolation and genetic homogeneity of the Finnish population.
Limitations
The study population was limited to Finnish families, which may not represent other populations.
Participant Demographics
The study included Finnish families with hereditary prostate cancer and healthy male blood donors.
Statistical Information
P-Value
0.02
Confidence Interval
95% CI 1.49−45.54
Statistical Significance
p=0.02
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website